- published: 06 Sep 2016
- views: 5
Create your page here
Saturday, 17 September 2016
-
remove the playlistLatest Videos
-
remove the playlistLongest Videos
- remove the playlistLatest Videos
- remove the playlistLongest Videos
back to playlist
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to withdraw the old medicine
based on large pools of donated plasma in favor of "safer" heat treated versions
but the FDA approved selling it to people over seas & companys like Cutter were dumping tainted" medicine into other countries
Harry M. Meyer Jr. the FDA's regulator of blood products asked that the issue be "quietly solved without alerting the Congress, the medical community and the public" , the FDA wanted the matter solved "quickly and quietly." clotting producers quietly settled many claims. most states had laws shielding blood products from traditional product liability claims Individual lawsuits continued to fail & In early 1995, the United States Court of Appeals for the Seventh Circuit in Chicago decertified one lawsuit, saying it might bankrupt the industry
In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.
current blood clotting agents are not made from donated blood so there is no risk of HIV infections even from Bayer & it never involved aspirin Vaccine depopulation or the Nazis & naturalnews is full of shit!
http://archive.li/tZFxi
http://en.wikipedia.org/wiki/Factor_VIII
http://en.wikipedia.org/wiki/Contaminated_haemophilia_blood_products
http://ahrp.org/bayer-documents-aids-tainted-blood-killed-thousands-of-hemophiliacs/
http://joewein.net/hoax/hoax-hiv-factor-eight.htm
- published: 06 Sep 2016
- views: 14
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard.
Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School.
His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the U.S. and sub-Saharan Africa.
Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.
- published: 02 Sep 2016
- views: 5
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective, global HIV vaccine. Through clinical trials at sites all over the world, efforts are focused on a successful Thai trial, called RV144, which recently provided renewed optimism that the scientific-underpinnings for an HIV Vaccine are coming closer to a reality. And what's amazing is that most of their work wouldn't be possible without the help of volunteers. If you want to live in a world that is free from HIV, free from AIDS . . . then get involved!
- published: 28 Aug 2016
- views: 5
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation.
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one.
There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced.
One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials.
- published: 11 Aug 2016
- views: 4
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South Africa. (Video courtesy of the International AIDS Society.)
- published: 11 Aug 2016
- views: 130
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response.
A research team led by scientists at the Duke Human Vaccine Institute has been unraveling that mystery, detailing new insights in a study published July 29 in the journal Science Immunology.
Studying 100 HIV-infected people -- half whose immune systems eventually made antibodies capable of broadly neutralizing the virus and half whose immune systems did not -- the researchers found several key immune differences that should help in the development of a how-to manual for an effective vaccine.
“This work gives us the beginning of an understanding of the immune mechanisms that control development of broadly neutralizing antibodies, which is a major goal of a successful HIV vaccine,” said Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study. “This moves forward important concepts for vaccine design to overcome a roadblock that has been present since we began this work 30 years ago.”
In earlier work, Haynes and colleagues studied a person with both HIV and a form of lupus erythematosus, which is an autoimmune disease. The person’s immune system both controlled the virus and developed broadly neutralizing antibodies.
The researchers have hypothesized that the same immune disruptions that caused the person to develop lupus were somehow enabling the broadly neutralizing antibodies to fulfill their potential and fight the virus.
Now, by directly studying large numbers of HIV-infected people whose immune systems made broadly neutralizing antibodies, the researchers found that they have similar immune alterations, or perturbations, as found in individuals with autoimmune disease.
“In essence, HIV cloaks its vulnerable sites that the immune system wants to see by making them resemble our own tissues, thereby creating an environment in which the virus is protected and the beneficial antibodies are treated as a threat to the body”, said lead author Anthony Moody, M.D., chief medical officer of the Duke Human Vaccine Institute.
“These findings suggest that for a broadly neutralizing antibody-inducing HIV vaccine to be successful, we will need to mimic with vaccination the immune perturbations that occur in the setting of HIV infection,” Haynes said.
“The important point here is that the first step to finding a way around a roadblock, is to be able to understand the biology behind the problem,” Haynes said. “We now know what we need to do. The next step is to figure out how to safely mimic what happens in infection when the right antibodies are induced.”
In addition to Haynes, study authors include M. Anthony Moody; Isabela Pedroza-Pacheco; Nathan A. Vandergrift; Cecilia Chui; Krissey E. Lloyd; Robert Parks; Kelly A. Soderberg; Ane T. Ogbe; Myron S. Cohen; Hua-Xin Liao; Feng Gao; Andrew J. McMichael; David C. Montefiori; Laurent Verkoczy; Garnett Kelsoe; Jinghe Huang; Patrick R. Shea; Mark Connors; and Persephone Borrow.
The study received support from the National Institute of Allergy and Infectious Diseases directly (AI100696) and through the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (AI100645 and AI067854), and from an MRC Programme grant (MR/K012037).
- published: 29 Jul 2016
- views: 62
HIV vaccine
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced.
One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials.
Overview
The urgency of the search for a vaccine against HIV stems from the AIDS-related death toll of over 25 million people since 1981. Indeed, in 2002, AIDS became the primary cause of mortality due to an infectious agent in Africa.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/HIV_vaccine
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
59:31Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe InstituteDan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel -
10:34Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to withdraw the old medicine based on large pools of donated plasma in favor of "safer" heat treated versions but the FDA approved selling it to people over seas & companys like Cutter were dumping tainted" medicine into other countries Harry M. Meyer Jr. the FDA's regulator of blood products asked that the issue be "quietly solved without alerting the Congress, the medical community and the public" , the FDA wanted the matter solved "quickly and quietly." clotting producers quietly settled many claims. most states had laws shielding blood products from traditional product liability claims Individual lawsuits continued to fail & In early 1995, the United States Court of Appeals for the Seventh Circuit in Chicago decertified one lawsuit, saying it might bankrupt the industry In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy. current blood clotting agents are not made from donated blood so there is no risk of HIV infections even from Bayer & it never involved aspirin Vaccine depopulation or the Nazis & naturalnews is full of shit! http://archive.li/tZFxi http://en.wikipedia.org/wiki/Factor_VIII http://en.wikipedia.org/wiki/Contaminated_haemophilia_blood_products http://ahrp.org/bayer-documents-aids-tainted-blood-killed-thousands-of-hemophiliacs/ http://joewein.net/hoax/hoax-hiv-factor-eight.htm -
28:05WEPL0104 - Toward an HIV Vaccine
WEPL0104 - Toward an HIV Vaccine -
38:3304 Dan Barouch: Novel HIV Vaccine Strategies
04 Dan Barouch: Novel HIV Vaccine Strategies04 Dan Barouch: Novel HIV Vaccine Strategies
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard. Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the U.S. and sub-Saharan Africa. Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases. -
5:28HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
HIV Vaccine Trials Network - Working Towards an AIDS-free GenerationHIV Vaccine Trials Network - Working Towards an AIDS-free Generation
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective, global HIV vaccine. Through clinical trials at sites all over the world, efforts are focused on a successful Thai trial, called RV144, which recently provided renewed optimism that the scientific-underpinnings for an HIV Vaccine are coming closer to a reality. And what's amazing is that most of their work wouldn't be possible without the help of volunteers. If you want to live in a world that is free from HIV, free from AIDS . . . then get involved! -
1:05Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115
Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115 -
1:31What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanationWhat is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation. An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced. One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials. -
12:31An HIV Vaccine: Mapping Uncharted Territory
An HIV Vaccine: Mapping Uncharted TerritoryAn HIV Vaccine: Mapping Uncharted Territory
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South Africa. (Video courtesy of the International AIDS Society.) -
1:20Sharing Our Hope and Dream for an HIV Vaccine
Sharing Our Hope and Dream for an HIV Vaccine -
3:36Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine developmentBarton Haynes: Tracking how HIV disrupts immune system informs vaccine development
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response. A research team led by scientists at the Duke Human Vaccine Institute has been unraveling that mystery, detailing new insights in a study published July 29 in the journal Science Immunology. Studying 100 HIV-infected people -- half whose immune systems eventually made antibodies capable of broadly neutralizing the virus and half whose immune systems did not -- the researchers found several key immune differences that should help in the development of a how-to manual for an effective vaccine. “This work gives us the beginning of an understanding of the immune mechanisms that control development of broadly neutralizing antibodies, which is a major goal of a successful HIV vaccine,” said Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study. “This moves forward important concepts for vaccine design to overcome a roadblock that has been present since we began this work 30 years ago.” In earlier work, Haynes and colleagues studied a person with both HIV and a form of lupus erythematosus, which is an autoimmune disease. The person’s immune system both controlled the virus and developed broadly neutralizing antibodies. The researchers have hypothesized that the same immune disruptions that caused the person to develop lupus were somehow enabling the broadly neutralizing antibodies to fulfill their potential and fight the virus. Now, by directly studying large numbers of HIV-infected people whose immune systems made broadly neutralizing antibodies, the researchers found that they have similar immune alterations, or perturbations, as found in individuals with autoimmune disease. “In essence, HIV cloaks its vulnerable sites that the immune system wants to see by making them resemble our own tissues, thereby creating an environment in which the virus is protected and the beneficial antibodies are treated as a threat to the body”, said lead author Anthony Moody, M.D., chief medical officer of the Duke Human Vaccine Institute. “These findings suggest that for a broadly neutralizing antibody-inducing HIV vaccine to be successful, we will need to mimic with vaccination the immune perturbations that occur in the setting of HIV infection,” Haynes said. “The important point here is that the first step to finding a way around a roadblock, is to be able to understand the biology behind the problem,” Haynes said. “We now know what we need to do. The next step is to figure out how to safely mimic what happens in infection when the right antibodies are induced.” In addition to Haynes, study authors include M. Anthony Moody; Isabela Pedroza-Pacheco; Nathan A. Vandergrift; Cecilia Chui; Krissey E. Lloyd; Robert Parks; Kelly A. Soderberg; Ane T. Ogbe; Myron S. Cohen; Hua-Xin Liao; Feng Gao; Andrew J. McMichael; David C. Montefiori; Laurent Verkoczy; Garnett Kelsoe; Jinghe Huang; Patrick R. Shea; Mark Connors; and Persephone Borrow. The study received support from the National Institute of Allergy and Infectious Diseases directly (AI100696) and through the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (AI100645 and AI067854), and from an MRC Programme grant (MR/K012037).
-
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel
published: 06 Sep 2016 -
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to withdraw the old medicine based on large pools of donated plasma in favor of "safer" heat treated versions but the FDA approved selling it to people over seas & companys like Cutter were dumping tainted" medicine into other countries Harry M. Meyer Jr. the FDA's regulator of blood products asked that the issue be "quietly solved without alerting the Congress, the medical community and the public" , the FDA wanted the matter solved "quickly and quietly." clotting producers quietly settled many claims. most states had laws shielding blood products from traditional product liability claims Individual lawsuits continued to fail ...
published: 06 Sep 2016 -
-
04 Dan Barouch: Novel HIV Vaccine Strategies
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard. Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus ...
published: 02 Sep 2016 -
HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective, global HIV vaccine. Through clinical trials at sites all over the world, efforts are focused on a successful Thai trial, called RV144, which recently provided renewed optimism that the scientific-underpinnings for an HIV Vaccine are coming closer to a reality. And what's amazing is that most of their work wouldn't be possible without the help of volunteers. If you want to live in a world that is free from HIV, free from AIDS . . . then get involved!
published: 28 Aug 2016 -
-
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation. An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced. One HIV vaccine candidate which showe...
published: 11 Aug 2016 -
An HIV Vaccine: Mapping Uncharted Territory
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South Africa. (Video courtesy of the International AIDS Society.)
published: 11 Aug 2016 -
-
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response. A research team led by scientists at the Duke Human Vaccine Institute has been unraveling that mystery, detailing new insights in a study published July 29 in the journal Science Immunology. Studying 100 HIV-infected people -- half whose immune systems eventually made antibodies capable of broadly neutralizing the virus and half whose immune systems did not -- the researchers found several key immune differences that should help in the development of a how-to manual for an effective vaccine. “This work gives us the beginning of an understanding of the immune mechanisms that...
published: 29 Jul 2016
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
- Order: Reorder
- Duration: 59:31
- Updated: 06 Sep 2016
- views: 5
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel
wn.com/Dan Barouch | Prospects For A Vaccine And A Cure For Hiv || Radcliffe Institute
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of the Center for Virology and Vaccine Research at Beth Israel
- published: 06 Sep 2016
- views: 5
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
- Order: Reorder
- Duration: 10:34
- Updated: 06 Sep 2016
- views: 14
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to with...
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to withdraw the old medicine
based on large pools of donated plasma in favor of "safer" heat treated versions
but the FDA approved selling it to people over seas & companys like Cutter were dumping tainted" medicine into other countries
Harry M. Meyer Jr. the FDA's regulator of blood products asked that the issue be "quietly solved without alerting the Congress, the medical community and the public" , the FDA wanted the matter solved "quickly and quietly." clotting producers quietly settled many claims. most states had laws shielding blood products from traditional product liability claims Individual lawsuits continued to fail & In early 1995, the United States Court of Appeals for the Seventh Circuit in Chicago decertified one lawsuit, saying it might bankrupt the industry
In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.
current blood clotting agents are not made from donated blood so there is no risk of HIV infections even from Bayer & it never involved aspirin Vaccine depopulation or the Nazis & naturalnews is full of shit!
http://archive.li/tZFxi
http://en.wikipedia.org/wiki/Factor_VIII
http://en.wikipedia.org/wiki/Contaminated_haemophilia_blood_products
http://ahrp.org/bayer-documents-aids-tainted-blood-killed-thousands-of-hemophiliacs/
http://joewein.net/hoax/hoax-hiv-factor-eight.htm
wn.com/Bayer Fda Aspirin Hiv Aids Hepatitis Hemophilia Vaccine Depopulation Iv Clot Cutter Factor Viii 8
HIV & hepatitis tainted blood products were in the system before proper screening was introduced in the mid-1980s & then companies had voluntary agreed to withdraw the old medicine
based on large pools of donated plasma in favor of "safer" heat treated versions
but the FDA approved selling it to people over seas & companys like Cutter were dumping tainted" medicine into other countries
Harry M. Meyer Jr. the FDA's regulator of blood products asked that the issue be "quietly solved without alerting the Congress, the medical community and the public" , the FDA wanted the matter solved "quickly and quietly." clotting producers quietly settled many claims. most states had laws shielding blood products from traditional product liability claims Individual lawsuits continued to fail & In early 1995, the United States Court of Appeals for the Seventh Circuit in Chicago decertified one lawsuit, saying it might bankrupt the industry
In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.
current blood clotting agents are not made from donated blood so there is no risk of HIV infections even from Bayer & it never involved aspirin Vaccine depopulation or the Nazis & naturalnews is full of shit!
http://archive.li/tZFxi
http://en.wikipedia.org/wiki/Factor_VIII
http://en.wikipedia.org/wiki/Contaminated_haemophilia_blood_products
http://ahrp.org/bayer-documents-aids-tainted-blood-killed-thousands-of-hemophiliacs/
http://joewein.net/hoax/hoax-hiv-factor-eight.htm
- published: 06 Sep 2016
- views: 14
WEPL0104 - Toward an HIV Vaccine
- Order: Reorder
- Duration: 28:05
- Updated: 02 Sep 2016
- views: 13
04 Dan Barouch: Novel HIV Vaccine Strategies
- Order: Reorder
- Duration: 38:33
- Updated: 02 Sep 2016
- views: 5
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medici...
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard.
Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School.
His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the U.S. and sub-Saharan Africa.
Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.
wn.com/04 Dan Barouch Novel Hiv Vaccine Strategies
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. He is also a professor of medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, and the Ragon Institute of MGH, MIT, and Harvard.
Dr. Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School.
His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. His laboratory has explored a series of novel vaccine technologies, including adjuvanted DNA vaccines, poxvirus vectors, and alternative serotype adenovirus vectors in both preclinical and clinical studies. In particular, he has advanced a series of novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing to phase 1 clinical trials that are currently underway in both the U.S. and sub-Saharan Africa.
Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.
- published: 02 Sep 2016
- views: 5
HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
- Order: Reorder
- Duration: 5:28
- Updated: 28 Aug 2016
- views: 5
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective...
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective, global HIV vaccine. Through clinical trials at sites all over the world, efforts are focused on a successful Thai trial, called RV144, which recently provided renewed optimism that the scientific-underpinnings for an HIV Vaccine are coming closer to a reality. And what's amazing is that most of their work wouldn't be possible without the help of volunteers. If you want to live in a world that is free from HIV, free from AIDS . . . then get involved!
wn.com/Hiv Vaccine Trials Network Working Towards An Aids Free Generation
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an AIDS-free generation - and they're doing it by developing an effective, global HIV vaccine. Through clinical trials at sites all over the world, efforts are focused on a successful Thai trial, called RV144, which recently provided renewed optimism that the scientific-underpinnings for an HIV Vaccine are coming closer to a reality. And what's amazing is that most of their work wouldn't be possible without the help of volunteers. If you want to live in a world that is free from HIV, free from AIDS . . . then get involved!
- published: 28 Aug 2016
- views: 5
Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115
- Order: Reorder
- Duration: 1:05
- Updated: 16 Aug 2016
- views: 2
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
- Order: Reorder
- Duration: 1:31
- Updated: 11 Aug 2016
- views: 4
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation.
An HIV vaccine is a vaccine which would either protect individu...
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation.
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one.
There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced.
One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials.
wn.com/What Is Hiv Vaccine What Does Hiv Vaccine Mean Hiv Vaccine Meaning, Definition Explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation.
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one.
There is evidence that a vaccine may be possible. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced.
One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown no efficacy, including the STEP study and HVTN 505 trials.
- published: 11 Aug 2016
- views: 4
An HIV Vaccine: Mapping Uncharted Territory
- Order: Reorder
- Duration: 12:31
- Updated: 11 Aug 2016
- views: 130
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South A...
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South Africa. (Video courtesy of the International AIDS Society.)
wn.com/An Hiv Vaccine Mapping Uncharted Territory
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine development at the 21st International AIDS Conference in Durban, South Africa. (Video courtesy of the International AIDS Society.)
- published: 11 Aug 2016
- views: 130
Sharing Our Hope and Dream for an HIV Vaccine
- Order: Reorder
- Duration: 1:20
- Updated: 05 Aug 2016
- views: 73
We are Janssen. We collaborate with the world for the health of everyone in it.
Find Out More:
Our Website: www.janssen.com
Twitter: @JanssenGlobal
LinkedIn:...
We are Janssen. We collaborate with the world for the health of everyone in it.
Find Out More:
Our Website: www.janssen.com
Twitter: @JanssenGlobal
LinkedIn: http://linkd.in/1Ln4OrC
wn.com/Sharing Our Hope And Dream For An Hiv Vaccine
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
- Order: Reorder
- Duration: 3:36
- Updated: 29 Jul 2016
- views: 62
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, ...
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response.
A research team led by scientists at the Duke Human Vaccine Institute has been unraveling that mystery, detailing new insights in a study published July 29 in the journal Science Immunology.
Studying 100 HIV-infected people -- half whose immune systems eventually made antibodies capable of broadly neutralizing the virus and half whose immune systems did not -- the researchers found several key immune differences that should help in the development of a how-to manual for an effective vaccine.
“This work gives us the beginning of an understanding of the immune mechanisms that control development of broadly neutralizing antibodies, which is a major goal of a successful HIV vaccine,” said Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study. “This moves forward important concepts for vaccine design to overcome a roadblock that has been present since we began this work 30 years ago.”
In earlier work, Haynes and colleagues studied a person with both HIV and a form of lupus erythematosus, which is an autoimmune disease. The person’s immune system both controlled the virus and developed broadly neutralizing antibodies.
The researchers have hypothesized that the same immune disruptions that caused the person to develop lupus were somehow enabling the broadly neutralizing antibodies to fulfill their potential and fight the virus.
Now, by directly studying large numbers of HIV-infected people whose immune systems made broadly neutralizing antibodies, the researchers found that they have similar immune alterations, or perturbations, as found in individuals with autoimmune disease.
“In essence, HIV cloaks its vulnerable sites that the immune system wants to see by making them resemble our own tissues, thereby creating an environment in which the virus is protected and the beneficial antibodies are treated as a threat to the body”, said lead author Anthony Moody, M.D., chief medical officer of the Duke Human Vaccine Institute.
“These findings suggest that for a broadly neutralizing antibody-inducing HIV vaccine to be successful, we will need to mimic with vaccination the immune perturbations that occur in the setting of HIV infection,” Haynes said.
“The important point here is that the first step to finding a way around a roadblock, is to be able to understand the biology behind the problem,” Haynes said. “We now know what we need to do. The next step is to figure out how to safely mimic what happens in infection when the right antibodies are induced.”
In addition to Haynes, study authors include M. Anthony Moody; Isabela Pedroza-Pacheco; Nathan A. Vandergrift; Cecilia Chui; Krissey E. Lloyd; Robert Parks; Kelly A. Soderberg; Ane T. Ogbe; Myron S. Cohen; Hua-Xin Liao; Feng Gao; Andrew J. McMichael; David C. Montefiori; Laurent Verkoczy; Garnett Kelsoe; Jinghe Huang; Patrick R. Shea; Mark Connors; and Persephone Borrow.
The study received support from the National Institute of Allergy and Infectious Diseases directly (AI100696) and through the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (AI100645 and AI067854), and from an MRC Programme grant (MR/K012037).
wn.com/Barton Haynes Tracking How Hiv Disrupts Immune System Informs Vaccine Development
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response.
A research team led by scientists at the Duke Human Vaccine Institute has been unraveling that mystery, detailing new insights in a study published July 29 in the journal Science Immunology.
Studying 100 HIV-infected people -- half whose immune systems eventually made antibodies capable of broadly neutralizing the virus and half whose immune systems did not -- the researchers found several key immune differences that should help in the development of a how-to manual for an effective vaccine.
“This work gives us the beginning of an understanding of the immune mechanisms that control development of broadly neutralizing antibodies, which is a major goal of a successful HIV vaccine,” said Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study. “This moves forward important concepts for vaccine design to overcome a roadblock that has been present since we began this work 30 years ago.”
In earlier work, Haynes and colleagues studied a person with both HIV and a form of lupus erythematosus, which is an autoimmune disease. The person’s immune system both controlled the virus and developed broadly neutralizing antibodies.
The researchers have hypothesized that the same immune disruptions that caused the person to develop lupus were somehow enabling the broadly neutralizing antibodies to fulfill their potential and fight the virus.
Now, by directly studying large numbers of HIV-infected people whose immune systems made broadly neutralizing antibodies, the researchers found that they have similar immune alterations, or perturbations, as found in individuals with autoimmune disease.
“In essence, HIV cloaks its vulnerable sites that the immune system wants to see by making them resemble our own tissues, thereby creating an environment in which the virus is protected and the beneficial antibodies are treated as a threat to the body”, said lead author Anthony Moody, M.D., chief medical officer of the Duke Human Vaccine Institute.
“These findings suggest that for a broadly neutralizing antibody-inducing HIV vaccine to be successful, we will need to mimic with vaccination the immune perturbations that occur in the setting of HIV infection,” Haynes said.
“The important point here is that the first step to finding a way around a roadblock, is to be able to understand the biology behind the problem,” Haynes said. “We now know what we need to do. The next step is to figure out how to safely mimic what happens in infection when the right antibodies are induced.”
In addition to Haynes, study authors include M. Anthony Moody; Isabela Pedroza-Pacheco; Nathan A. Vandergrift; Cecilia Chui; Krissey E. Lloyd; Robert Parks; Kelly A. Soderberg; Ane T. Ogbe; Myron S. Cohen; Hua-Xin Liao; Feng Gao; Andrew J. McMichael; David C. Montefiori; Laurent Verkoczy; Garnett Kelsoe; Jinghe Huang; Patrick R. Shea; Mark Connors; and Persephone Borrow.
The study received support from the National Institute of Allergy and Infectious Diseases directly (AI100696) and through the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (AI100645 and AI067854), and from an MRC Programme grant (MR/K012037).
- published: 29 Jul 2016
- views: 62
-
Towards an HIV Vaccine: A Scientific Journey – Dr. Anthony S. Fauci, M.D.
Towards an HIV Vaccine: A Scientific Journey The following is the opening keynote address delivered via video by Dr. Anthony S. Fauci of NIAID, National Institutes of Health on March 23, 2015 at the Keystone Symposia joint meetings on “HIV Vaccines” and “The Golden Anniversary of B Cell Discovery” in Banff, Alberta, Canada. Dr. Fauci was unable to attend in person due to his work caring for an Ebola patient at the NIH Clinical Center in Bethesda, Maryland. About Anthony S. Fauci (from NIH Site): Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential ...
published: 16 Apr 2015 -
Progress in Developing an HIV Vaccine: Empiricism and a Bit of Optimism
HIV continues to be the epidemic of our lifetime. Even today, 2 million new infections occur worldwide and there are over 50,000 new cases a year in the US. Developing an HIV vaccine has been a scientific challenge, but new technologies and approaches are leading to guarded optimism about achieving this goal. Dr. Lawrence Corey, professor of medicine and laboratory medicine at the University of Washington, past president of the Fred Hutchinson Cancer Research Center, and head of the HIV Vaccine Trials Network, will discuss the state of the HIV vaccine field and the role Seattle plays in this field. Lawrence Corey, MD, professor, Departments of Medicine and Laboratory Medicine, adjunct professor, Departments of Pediatrics and Microbiology, University of Washington 03/30/2016 http://depts...
published: 10 May 2016 -
Mandatory AIDS Vaccine Coming Soon
Barbara Loe Fisher of the National Vaccine Information Center discusses the growing controversy over vaccines, including the alleged link to the epidemic of autism. Will Obamacare mandate vaccines? What about an HIV/AIDS vaccine? Please go to www.nvic.org and America's Survival, Inc., ASI, (www.usasurvival.org) for more information. ASI has been fighting against a mandatory HIV/AIDS vaccinefor ovr a decade. The AIDS vaccine will be first tried on children, whose immune systems are not fully developed. The elderly and those who are already sick with AIDS may get even weaker or sicker after exposure to an AIDS vaccine. On the other hand, a healthy immune system exposed to the vaccine may induce AIDS itself. A vaccine may spread the disease to more people. Help us stop this vaccine madness.
published: 11 Apr 2016 -
The Origin of AIDS,Polio Vaccine The Smoking Gun
published: 10 Feb 2013 -
HIV Vaccine Research Update: Where Do We Stand in 2014?
Presentation Title: "HIV Vaccine Research Update: Where Do We Stand in 2014?" Event Date: Friday, May 2, 2014 Guest Speaker: Magdalena Sobieszczyk, MD, MPH is an Associate Professor of Medicine in the Infectious Diseases Division at the Columbia University College of Physicians and Surgeons. She is also the Principal Investigator of the NIH-funded Columbia HVTN and ACTG Clinical Research Site. Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP). Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP. Host Institution: Albany Medical College, Division of HIV Medicine; bro...
published: 31 Aug 2015 -
Vaccines and HIV Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
published: 01 Dec 2008 -
Seth Berkley: HIV and flu -- the vaccine strategy
http://www.ted.com Seth Berkley explains how smart advances in vaccine design, production and distribution are bringing us closer than ever to eliminating a host of global threats -- from AIDS to malaria to flu pandemics. TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world's leading thinkers and doers give the talk of their lives in 18 minutes. Featured speakers have included Al Gore on climate change, Philippe Starck on design, Jill Bolte Taylor on observing her own stroke, Nicholas Negroponte on One Laptop per Child, Jane Goodall on chimpanzees, Bill Gates on malaria and mosquitoes, Pattie Maes on the "Sixth Sense" wearable tech, and "Lost" producer JJ Abrams on the allure of mystery. TED stands for Technology, Entertainment, Des...
published: 27 May 2010 -
Webinar: HIV Vaccine Research Update — What's new and why it matters
Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of Medicine at the University of Cape Town. She is also President-elect of the International AIDS Society. Amongst many HIV prevention research activities that she leads, she is the principal investigator of the HVTN 100 vaccine trial, and in this webinar she discussed the latest in HIV vaccine research and the most recent updates on the plan to start a new vaccine efficacy trial later this year.
published: 02 Jun 2016 -
Ending Epidemics Through Technology: Developing an HIV Vaccine
Biomedical research towards the prevention and treatment of HIV, tuberculosis, malaria, and other major global health challenges remains our long-term hope for bringing these epidemics to an end. Understanding when new technologies are likely to emerge from the research and development pipeline, and how they might impact ongoing efforts, is vital to ensuring their rapid uptake and integration. Please join us for a discussion on the status of HIV vaccines and how the U.S. will need to change its response to the global epidemic. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease (NIAID), will deliver the keynote address. Afterwards, Dr. Fauci will join a distinguished panel with Mr. Mitchell Warren, Executive Director of AVAC, a New York-based advocacy...
published: 05 Nov 2014 -
CAHR2015 - Canadian HIV Vaccine Initiative – Vaccine Research Plenary
HIV Vaccine and Prevention Technologies: Forging a Path Forward This session featured Drs. Marc Gurwith and Frank Plummer. Replication Competent Vector Vaccine for HIV: Development of an Orally Administered Replication-competent Adenovirus Serotype 4 Vector Vaccine Candidate for HIV Marc Gurwith is Chief Medical Officer at PaxVax. He is a Fellow of the Infectious Disease Society of America, and is currently a member of The Brighton Collaboration Viral Vaccine Vector Safety Working Group and the Scientific Advisory Board for the Keystone Symposia. Towards New Technologies for HIV Prevention Frank Plummer is a Senior Advisor to the Chief Public Health Officer, the Agency Deputy Head of the Public Health Agency of Canada and a Distinguished Professor at the University of Manitoba.
published: 02 May 2015
Towards an HIV Vaccine: A Scientific Journey – Dr. Anthony S. Fauci, M.D.
- Order: Reorder
- Duration: 31:56
- Updated: 16 Apr 2015
- views: 3927
Towards an HIV Vaccine: A Scientific Journey
The following is the opening keynote address delivered via video by Dr. Anthony S. Fauci of NIAID, National Instit...
Towards an HIV Vaccine: A Scientific Journey
The following is the opening keynote address delivered via video by Dr. Anthony S. Fauci of NIAID, National Institutes of Health on March 23, 2015 at the Keystone Symposia joint meetings on “HIV Vaccines” and “The Golden Anniversary of B Cell Discovery” in Banff, Alberta, Canada. Dr. Fauci was unable to attend in person due to his work caring for an Ebola patient at the NIH Clinical Center in Bethesda, Maryland.
About Anthony S. Fauci (from NIH Site):
Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2013 was approximately $4.5 billion. Dr. Fauci serves as one of the key advisors to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has already been responsible for saving millions of lives throughout the developing world.
Read more about Dr. Fauci:
http://www.niaid.nih.gov/about/directors/biography/Pages/biography.aspx
About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.
Visit our website:
https://www.keystonesymposia.org
For more videos:
https://www.youtube.com/user/KeystoneSymposia
Follow us on Twitter:
https://twitter.com/keystonesymp
Like us on Facebook:
https://www.facebook.com/KeystoneSymposia
Link to us on LinkedIn:
https://www.linkedin.com/company/1279010?trk=tyah&trkInfo;=idx%3A1-1-1%2CtarId%3A1426180450354%2Ctas%3Akeystone+symposia
Outro music:
"Slider" by Blue Dot Sessions (http://www.sessions.blue/sessions/)
wn.com/Towards An Hiv Vaccine A Scientific Journey – Dr. Anthony S. Fauci, M.D.
Towards an HIV Vaccine: A Scientific Journey
The following is the opening keynote address delivered via video by Dr. Anthony S. Fauci of NIAID, National Institutes of Health on March 23, 2015 at the Keystone Symposia joint meetings on “HIV Vaccines” and “The Golden Anniversary of B Cell Discovery” in Banff, Alberta, Canada. Dr. Fauci was unable to attend in person due to his work caring for an Ebola patient at the NIH Clinical Center in Bethesda, Maryland.
About Anthony S. Fauci (from NIH Site):
Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2013 was approximately $4.5 billion. Dr. Fauci serves as one of the key advisors to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has already been responsible for saving millions of lives throughout the developing world.
Read more about Dr. Fauci:
http://www.niaid.nih.gov/about/directors/biography/Pages/biography.aspx
About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.
Visit our website:
https://www.keystonesymposia.org
For more videos:
https://www.youtube.com/user/KeystoneSymposia
Follow us on Twitter:
https://twitter.com/keystonesymp
Like us on Facebook:
https://www.facebook.com/KeystoneSymposia
Link to us on LinkedIn:
https://www.linkedin.com/company/1279010?trk=tyah&trkInfo;=idx%3A1-1-1%2CtarId%3A1426180450354%2Ctas%3Akeystone+symposia
Outro music:
"Slider" by Blue Dot Sessions (http://www.sessions.blue/sessions/)
- published: 16 Apr 2015
- views: 3927
Progress in Developing an HIV Vaccine: Empiricism and a Bit of Optimism
- Order: Reorder
- Duration: 59:12
- Updated: 10 May 2016
- views: 185
HIV continues to be the epidemic of our lifetime. Even today, 2 million new infections occur worldwide and there are over 50,000 new cases a year in the US. Dev...
HIV continues to be the epidemic of our lifetime. Even today, 2 million new infections occur worldwide and there are over 50,000 new cases a year in the US. Developing an HIV vaccine has been a scientific challenge, but new technologies and approaches are leading to guarded optimism about achieving this goal. Dr. Lawrence Corey, professor of medicine and laboratory medicine at the University of Washington, past president of the Fred Hutchinson Cancer Research Center, and head of the HIV Vaccine Trials Network, will discuss the state of the HIV vaccine field and the role Seattle plays in this field.
Lawrence Corey, MD, professor, Departments of Medicine and Laboratory Medicine, adjunct professor, Departments of Pediatrics and Microbiology, University of Washington
03/30/2016
http://depts.washington.edu/labweb/Education/ContEdu/
http://uwtv.org
wn.com/Progress In Developing An Hiv Vaccine Empiricism And A Bit Of Optimism
HIV continues to be the epidemic of our lifetime. Even today, 2 million new infections occur worldwide and there are over 50,000 new cases a year in the US. Developing an HIV vaccine has been a scientific challenge, but new technologies and approaches are leading to guarded optimism about achieving this goal. Dr. Lawrence Corey, professor of medicine and laboratory medicine at the University of Washington, past president of the Fred Hutchinson Cancer Research Center, and head of the HIV Vaccine Trials Network, will discuss the state of the HIV vaccine field and the role Seattle plays in this field.
Lawrence Corey, MD, professor, Departments of Medicine and Laboratory Medicine, adjunct professor, Departments of Pediatrics and Microbiology, University of Washington
03/30/2016
http://depts.washington.edu/labweb/Education/ContEdu/
http://uwtv.org
- published: 10 May 2016
- views: 185
Mandatory AIDS Vaccine Coming Soon
- Order: Reorder
- Duration: 35:00
- Updated: 11 Apr 2016
- views: 1292
Barbara Loe Fisher of the National Vaccine Information Center discusses the growing controversy over vaccines, including the alleged link to the epidemic of aut...
Barbara Loe Fisher of the National Vaccine Information Center discusses the growing controversy over vaccines, including the alleged link to the epidemic of autism. Will Obamacare mandate vaccines? What about an HIV/AIDS vaccine? Please go to www.nvic.org and America's Survival, Inc., ASI, (www.usasurvival.org) for more information. ASI has been fighting against a mandatory HIV/AIDS vaccinefor ovr a decade. The AIDS vaccine will be first tried on children, whose immune systems are not fully developed. The elderly and those who are already sick with AIDS may get even weaker or sicker after exposure to an AIDS vaccine. On the other hand, a healthy immune system exposed to the vaccine may induce AIDS itself. A vaccine may spread the disease to more people. Help us stop this vaccine madness.
wn.com/Mandatory Aids Vaccine Coming Soon
Barbara Loe Fisher of the National Vaccine Information Center discusses the growing controversy over vaccines, including the alleged link to the epidemic of autism. Will Obamacare mandate vaccines? What about an HIV/AIDS vaccine? Please go to www.nvic.org and America's Survival, Inc., ASI, (www.usasurvival.org) for more information. ASI has been fighting against a mandatory HIV/AIDS vaccinefor ovr a decade. The AIDS vaccine will be first tried on children, whose immune systems are not fully developed. The elderly and those who are already sick with AIDS may get even weaker or sicker after exposure to an AIDS vaccine. On the other hand, a healthy immune system exposed to the vaccine may induce AIDS itself. A vaccine may spread the disease to more people. Help us stop this vaccine madness.
- published: 11 Apr 2016
- views: 1292
The Origin of AIDS,Polio Vaccine The Smoking Gun
- Order: Reorder
- Duration: 43:50
- Updated: 10 Feb 2013
- views: 16454
- published: 10 Feb 2013
- views: 16454
HIV Vaccine Research Update: Where Do We Stand in 2014?
- Order: Reorder
- Duration: 62:24
- Updated: 31 Aug 2015
- views: 169
Presentation Title: "HIV Vaccine Research Update: Where Do We Stand in 2014?"
Event Date: Friday, May 2, 2014
Guest Speaker: Magdalena Sobieszczyk, MD, MPH is...
Presentation Title: "HIV Vaccine Research Update: Where Do We Stand in 2014?"
Event Date: Friday, May 2, 2014
Guest Speaker: Magdalena Sobieszczyk, MD, MPH is an Associate Professor of Medicine in the Infectious Diseases Division at the Columbia University College of Physicians and Surgeons. She is also the Principal Investigator of the NIH-funded Columbia HVTN and ACTG Clinical Research Site. Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP). Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP.
Host Institution: Albany Medical College, Division of HIV Medicine; broadcast from the Hilton Garden Inn at Albany Medical Center, Albany, New York.
DISCLAIMER: All materials included on this site are intended for informational/educational purposes only. Viewers are encouraged to confirm information contained herein with other sources. Consumers should review such information carefully with their physicians or other professional healthcare providers. This information is not intended to and should not be used to replace medical advice offered by physicians or other health providers. Columbia University Medical Center and its Divisions will not be liable for any direct, indirect, consequential, special, exemplary or other damages arising therefrom.
wn.com/Hiv Vaccine Research Update Where Do We Stand In 2014
Presentation Title: "HIV Vaccine Research Update: Where Do We Stand in 2014?"
Event Date: Friday, May 2, 2014
Guest Speaker: Magdalena Sobieszczyk, MD, MPH is an Associate Professor of Medicine in the Infectious Diseases Division at the Columbia University College of Physicians and Surgeons. She is also the Principal Investigator of the NIH-funded Columbia HVTN and ACTG Clinical Research Site. Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP). Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP.
Host Institution: Albany Medical College, Division of HIV Medicine; broadcast from the Hilton Garden Inn at Albany Medical Center, Albany, New York.
DISCLAIMER: All materials included on this site are intended for informational/educational purposes only. Viewers are encouraged to confirm information contained herein with other sources. Consumers should review such information carefully with their physicians or other professional healthcare providers. This information is not intended to and should not be used to replace medical advice offered by physicians or other health providers. Columbia University Medical Center and its Divisions will not be liable for any direct, indirect, consequential, special, exemplary or other damages arising therefrom.
- published: 31 Aug 2015
- views: 169
Vaccines and HIV Evolution
- Order: Reorder
- Duration: 59:14
- Updated: 01 Dec 2008
- views: 4329
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to...
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
wn.com/Vaccines And Hiv Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institute and director for the Center for AIDS research, discusses efforts to develop an effective vaccine against HIV. Despite decades of research, scientists have not closed in on developing a much-needed vaccine for HIV. A key challenge is how to address the rapid evolution of the virus within individuals, which makes it difficult to pinpoint a stable protein sequence for vaccine development.
- published: 01 Dec 2008
- views: 4329
Seth Berkley: HIV and flu -- the vaccine strategy
- Order: Reorder
- Duration: 21:37
- Updated: 27 May 2010
- views: 33069
http://www.ted.com Seth Berkley explains how smart advances in vaccine design, production and distribution are bringing us closer than ever to eliminating a hos...
http://www.ted.com Seth Berkley explains how smart advances in vaccine design, production and distribution are bringing us closer than ever to eliminating a host of global threats -- from AIDS to malaria to flu pandemics.
TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world's leading thinkers and doers give the talk of their lives in 18 minutes. Featured speakers have included Al Gore on climate change, Philippe Starck on design, Jill Bolte Taylor on observing her own stroke, Nicholas Negroponte on One Laptop per Child, Jane Goodall on chimpanzees, Bill Gates on malaria and mosquitoes, Pattie Maes on the "Sixth Sense" wearable tech, and "Lost" producer JJ Abrams on the allure of mystery. TED stands for Technology, Entertainment, Design, and TEDTalks cover these topics as well as science, business, development and the arts. Closed captions and translated subtitles in a variety of languages are now available on TED.com, at http://www.ted.com/translate. Watch a highlight reel of the Top 10 TEDTalks at http://www.ted.com/index.php/talks/top10
wn.com/Seth Berkley Hiv And Flu The Vaccine Strategy
http://www.ted.com Seth Berkley explains how smart advances in vaccine design, production and distribution are bringing us closer than ever to eliminating a host of global threats -- from AIDS to malaria to flu pandemics.
TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world's leading thinkers and doers give the talk of their lives in 18 minutes. Featured speakers have included Al Gore on climate change, Philippe Starck on design, Jill Bolte Taylor on observing her own stroke, Nicholas Negroponte on One Laptop per Child, Jane Goodall on chimpanzees, Bill Gates on malaria and mosquitoes, Pattie Maes on the "Sixth Sense" wearable tech, and "Lost" producer JJ Abrams on the allure of mystery. TED stands for Technology, Entertainment, Design, and TEDTalks cover these topics as well as science, business, development and the arts. Closed captions and translated subtitles in a variety of languages are now available on TED.com, at http://www.ted.com/translate. Watch a highlight reel of the Top 10 TEDTalks at http://www.ted.com/index.php/talks/top10
- published: 27 May 2010
- views: 33069
Webinar: HIV Vaccine Research Update — What's new and why it matters
- Order: Reorder
- Duration: 67:05
- Updated: 02 Jun 2016
- views: 43
Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of M...
Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of Medicine at the University of Cape Town. She is also President-elect of the International AIDS Society.
Amongst many HIV prevention research activities that she leads, she is the principal investigator of the HVTN 100 vaccine trial, and in this webinar she discussed the latest in HIV vaccine research and the most recent updates on the plan to start a new vaccine efficacy trial later this year.
wn.com/Webinar Hiv Vaccine Research Update — What's New And Why It Matters
Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of Medicine at the University of Cape Town. She is also President-elect of the International AIDS Society.
Amongst many HIV prevention research activities that she leads, she is the principal investigator of the HVTN 100 vaccine trial, and in this webinar she discussed the latest in HIV vaccine research and the most recent updates on the plan to start a new vaccine efficacy trial later this year.
- published: 02 Jun 2016
- views: 43
Ending Epidemics Through Technology: Developing an HIV Vaccine
- Order: Reorder
- Duration: 99:16
- Updated: 05 Nov 2014
- views: 1871
Biomedical research towards the prevention and treatment of HIV, tuberculosis, malaria, and other major global health challenges remains our long-term hope for ...
Biomedical research towards the prevention and treatment of HIV, tuberculosis, malaria, and other major global health challenges remains our long-term hope for bringing these epidemics to an end. Understanding when new technologies are likely to emerge from the research and development pipeline, and how they might impact ongoing efforts, is vital to ensuring their rapid uptake and integration.
Please join us for a discussion on the status of HIV vaccines and how the U.S. will need to change its response to the global epidemic. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease (NIAID), will deliver the keynote address. Afterwards, Dr. Fauci will join a distinguished panel with Mr. Mitchell Warren, Executive Director of AVAC, a New York-based advocacy group focused on HIV prevention, and Ms. Margie McGlynn, President and CEO of the International AIDS Vaccine Initiative (IAVI), a product development partnership focused on facilitating discovery of a safe, effective HIV vaccine. Mr. Todd Summers, Senior Advisor at the CSIS Global Health Policy Center, will moderate.
Refreshments will be served after the event closes.
https://csis.org/event/ending-epidemics-through-technology-developing-hiv-vaccine
wn.com/Ending Epidemics Through Technology Developing An Hiv Vaccine
Biomedical research towards the prevention and treatment of HIV, tuberculosis, malaria, and other major global health challenges remains our long-term hope for bringing these epidemics to an end. Understanding when new technologies are likely to emerge from the research and development pipeline, and how they might impact ongoing efforts, is vital to ensuring their rapid uptake and integration.
Please join us for a discussion on the status of HIV vaccines and how the U.S. will need to change its response to the global epidemic. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease (NIAID), will deliver the keynote address. Afterwards, Dr. Fauci will join a distinguished panel with Mr. Mitchell Warren, Executive Director of AVAC, a New York-based advocacy group focused on HIV prevention, and Ms. Margie McGlynn, President and CEO of the International AIDS Vaccine Initiative (IAVI), a product development partnership focused on facilitating discovery of a safe, effective HIV vaccine. Mr. Todd Summers, Senior Advisor at the CSIS Global Health Policy Center, will moderate.
Refreshments will be served after the event closes.
https://csis.org/event/ending-epidemics-through-technology-developing-hiv-vaccine
- published: 05 Nov 2014
- views: 1871
CAHR2015 - Canadian HIV Vaccine Initiative – Vaccine Research Plenary
- Order: Reorder
- Duration: 57:58
- Updated: 02 May 2015
- views: 134
HIV Vaccine and Prevention Technologies: Forging a Path Forward
This session featured Drs. Marc Gurwith and Frank Plummer.
Replication Competent Vector Vaccin...
HIV Vaccine and Prevention Technologies: Forging a Path Forward
This session featured Drs. Marc Gurwith and Frank Plummer.
Replication Competent Vector Vaccine for HIV: Development of an Orally Administered Replication-competent Adenovirus Serotype 4 Vector Vaccine Candidate for HIV
Marc Gurwith is Chief Medical Officer at PaxVax. He is a Fellow of the Infectious Disease Society of America, and is currently a member of The Brighton Collaboration Viral Vaccine Vector Safety Working Group and the Scientific Advisory Board for the Keystone Symposia.
Towards New Technologies for HIV Prevention
Frank Plummer is a Senior Advisor to the Chief Public Health Officer, the Agency Deputy Head of the Public Health Agency of Canada and a Distinguished Professor at the University of Manitoba.
wn.com/Cahr2015 Canadian Hiv Vaccine Initiative – Vaccine Research Plenary
HIV Vaccine and Prevention Technologies: Forging a Path Forward
This session featured Drs. Marc Gurwith and Frank Plummer.
Replication Competent Vector Vaccine for HIV: Development of an Orally Administered Replication-competent Adenovirus Serotype 4 Vector Vaccine Candidate for HIV
Marc Gurwith is Chief Medical Officer at PaxVax. He is a Fellow of the Infectious Disease Society of America, and is currently a member of The Brighton Collaboration Viral Vaccine Vector Safety Working Group and the Scientific Advisory Board for the Keystone Symposia.
Towards New Technologies for HIV Prevention
Frank Plummer is a Senior Advisor to the Chief Public Health Officer, the Agency Deputy Head of the Public Health Agency of Canada and a Distinguished Professor at the University of Manitoba.
- published: 02 May 2015
- views: 134
back
- Playlist
- Chat
back
- Playlist
- Chat
59:31
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
A lecture by Dan Barouch, professor of medicine at Harvard Medical School and director of ...
published: 06 Sep 2016
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
Dan Barouch | Prospects for a Vaccine and a Cure for HIV || Radcliffe Institute
- Report rights infringement
- published: 06 Sep 2016
- views: 5
10:34
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
HIV & hepatitis tainted blood products were in the system before proper screening was intr...
published: 06 Sep 2016
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
Bayer FDA aspirin HIV AIDS hepatitis hemophilia Vaccine depopulation IV clot Cutter Factor VIII 8
- Report rights infringement
- published: 06 Sep 2016
- views: 14
28:05
WEPL0104 - Toward an HIV Vaccine
WEPL0104 - Toward an HIV Vaccine
published: 02 Sep 2016
WEPL0104 - Toward an HIV Vaccine
WEPL0104 - Toward an HIV Vaccine
- Report rights infringement
- published: 02 Sep 2016
- views: 13
38:33
04 Dan Barouch: Novel HIV Vaccine Strategies
Dan Barouch, M.D., Ph.D., is director of the Center for Virology and Vaccine Research at B...
published: 02 Sep 2016
04 Dan Barouch: Novel HIV Vaccine Strategies
04 Dan Barouch: Novel HIV Vaccine Strategies
- Report rights infringement
- published: 02 Sep 2016
- views: 5
5:28
HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
Researchers at the HIV Vaccine Trials Network are working toward the goal of welcoming an ...
published: 28 Aug 2016
HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
HIV Vaccine Trials Network - Working Towards an AIDS-free Generation
- Report rights infringement
- published: 28 Aug 2016
- views: 5
1:05
Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115
Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115
published: 16 Aug 2016
Timetable 21 Robotic Grocery Retailer Within just Iowa And HIV Vaccine Trial 062115
1:31
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explana...
published: 11 Aug 2016
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
What is HIV VACCINE? What does HIV VACCINE mean? HIV VACCINE meaning, definition & explanation
- Report rights infringement
- published: 11 Aug 2016
- views: 4
12:31
An HIV Vaccine: Mapping Uncharted Territory
NIAID Director Anthony S. Fauci, M.D., discusses challenges and progress in HIV vaccine de...
published: 11 Aug 2016
An HIV Vaccine: Mapping Uncharted Territory
An HIV Vaccine: Mapping Uncharted Territory
- Report rights infringement
- published: 11 Aug 2016
- views: 130
1:20
Sharing Our Hope and Dream for an HIV Vaccine
We are Janssen. We collaborate with the world for the health of everyone in it.
Find Out ...
published: 05 Aug 2016
Sharing Our Hope and Dream for an HIV Vaccine
Sharing Our Hope and Dream for an HIV Vaccine
- Report rights infringement
- published: 05 Aug 2016
- views: 73
3:36
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
One of the main mysteries confounding development of an HIV vaccine is why some people inf...
published: 29 Jul 2016
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
Barton Haynes: Tracking how HIV disrupts immune system informs vaccine development
- Report rights infringement
- published: 29 Jul 2016
- views: 62
back
- Playlist
- Chat
31:56
Towards an HIV Vaccine: A Scientific Journey – Dr. Anthony S. Fauci, M.D.
Towards an HIV Vaccine: A Scientific Journey
The following is the opening keynote address...
published: 16 Apr 2015
Towards an HIV Vaccine: A Scientific Journey – Dr. Anthony S. Fauci, M.D.
Towards an HIV Vaccine: A Scientific Journey – Dr. Anthony S. Fauci, M.D.
- Report rights infringement
- published: 16 Apr 2015
- views: 3927
59:12
Progress in Developing an HIV Vaccine: Empiricism and a Bit of Optimism
HIV continues to be the epidemic of our lifetime. Even today, 2 million new infections occ...
published: 10 May 2016
Progress in Developing an HIV Vaccine: Empiricism and a Bit of Optimism
Progress in Developing an HIV Vaccine: Empiricism and a Bit of Optimism
- Report rights infringement
- published: 10 May 2016
- views: 185
35:00
Mandatory AIDS Vaccine Coming Soon
Barbara Loe Fisher of the National Vaccine Information Center discusses the growing contro...
published: 11 Apr 2016
Mandatory AIDS Vaccine Coming Soon
Mandatory AIDS Vaccine Coming Soon
- Report rights infringement
- published: 11 Apr 2016
- views: 1292
43:50
The Origin of AIDS,Polio Vaccine The Smoking Gun
published: 10 Feb 2013
The Origin of AIDS,Polio Vaccine The Smoking Gun
The Origin of AIDS,Polio Vaccine The Smoking Gun
- Report rights infringement
- published: 10 Feb 2013
- views: 16454
62:24
HIV Vaccine Research Update: Where Do We Stand in 2014?
Presentation Title: "HIV Vaccine Research Update: Where Do We Stand in 2014?"
Event Date:...
published: 31 Aug 2015
HIV Vaccine Research Update: Where Do We Stand in 2014?
HIV Vaccine Research Update: Where Do We Stand in 2014?
- Report rights infringement
- published: 31 Aug 2015
- views: 169
59:14
Vaccines and HIV Evolution
In this informative talk, Bruce Walker, investigator for the Howard Hughes Medical Institu...
published: 01 Dec 2008
Vaccines and HIV Evolution
Vaccines and HIV Evolution
- Report rights infringement
- published: 01 Dec 2008
- views: 4329
21:37
Seth Berkley: HIV and flu -- the vaccine strategy
http://www.ted.com Seth Berkley explains how smart advances in vaccine design, production ...
published: 27 May 2010
Seth Berkley: HIV and flu -- the vaccine strategy
Seth Berkley: HIV and flu -- the vaccine strategy
- Report rights infringement
- published: 27 May 2010
- views: 33069
67:05
Webinar: HIV Vaccine Research Update — What's new and why it matters
Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief O...
published: 02 Jun 2016
Webinar: HIV Vaccine Research Update — What's new and why it matters
Webinar: HIV Vaccine Research Update — What's new and why it matters
- Report rights infringement
- published: 02 Jun 2016
- views: 43
99:16
Ending Epidemics Through Technology: Developing an HIV Vaccine
Biomedical research towards the prevention and treatment of HIV, tuberculosis, malaria, an...
published: 05 Nov 2014
Ending Epidemics Through Technology: Developing an HIV Vaccine
Ending Epidemics Through Technology: Developing an HIV Vaccine
- Report rights infringement
- published: 05 Nov 2014
- views: 1871
57:58
CAHR2015 - Canadian HIV Vaccine Initiative – Vaccine Research Plenary
HIV Vaccine and Prevention Technologies: Forging a Path Forward
This session featured Drs...
published: 02 May 2015
CAHR2015 - Canadian HIV Vaccine Initiative – Vaccine Research Plenary
CAHR2015 - Canadian HIV Vaccine Initiative – Vaccine Research Plenary
- Report rights infringement
- published: 02 May 2015
- views: 134
Towards an HIV Vaccine: A Scientific Journey – Dr....
Progress in Developing an HIV Vaccine: Empiricism...
Mandatory AIDS Vaccine Coming Soon...
The Origin of AIDS,Polio Vaccine The Smoking Gun...
HIV Vaccine Research Update: Where Do We Stand in ...
Vaccines and HIV Evolution...
Seth Berkley: HIV and flu -- the vaccine strategy...
Webinar: HIV Vaccine Research Update — What's new ...
Ending Epidemics Through Technology: Developing an...
CAHR2015 - Canadian HIV Vaccine Initiative – Vacci...
photo: NASA / JPL-Caltech/MSSS
UFO Enthusiast Claims Discovery Of Ancient Alien Writing On ‘Abandoned Spacecraft’ On Mars
Edit Inquisitr 17 Sep 2016
A UFO enthusiast has claimed to have discovered what appears to be an “abandoned spaceship” on Mars. And that’s not all. The supposed craft, captured in a NASA Mars photo, has strange markings in the manner of hieroglyphs on its surface that the enthusiast believes could very well be a form of alien writing ... UFOmania described the object ... Scott C ... One commenter insisted all that was discovered was a rock....
photo: UN / Kim Haughton
U.N. chief: Israeli's comment on ethnic cleansing 'outrageous'
Edit Arkansas Online 17 Sep 2016
UNITED NATIONS -- Secretary-General Ban Ki-moon on Thursday called Israeli Prime Minister Benjamin Netanyahu's insistence that Palestinians want the "ethnic cleansing" of Jews in the West Bank "unacceptable and outrageous.". Ban told the U.N. Security Council that he wanted to be absolutely clear. "Settlements are illegal under international law." ... U.S ... Israel's U.N ... Power said the U.S ... A Section on 09/17/2016 ....
photo: White House / Pete Souza
Obama to decide on cuts to US nuclear arsenal in October
Edit The Guardian 17 Sep 2016
Limited politically feasible options on table for president to cement a disarmer legacy, most far-reaching of which is a one-third cut to deployed strategic arsenal. Barack Obama is expected to make a final decision next month on possible cuts to the US nuclear arsenal, in an attempt to consolidate his legacy as a disarmer before leaving office. West failing to deliver nuclear-deal promises, says Iran vice president. Read more ... He added....
photo: GFDL / Whit Welles
[VIDEO] Humpback Whales Interrupt Man Doing Pushups On His Kayak
Edit WorldNews.com 16 Sep 2016
The challenge asks participants to complete 22 pushups for 22 days.Pelayo was switching it up a little bit by performing his pushups on a kayak in the middle of the ocean off Grover Beach near San Luis Obispo, California....
photo: GFDL / Ich fahre hummer
Deutsche Bank refuses to pay $14B settlement
Edit Star Advertiser 17 Sep 2016
Deutsche Bank refuses to pay $14B claim. Deutsche Bank AG said Friday it does not intend to pay $14 billion to settle civil claims with the U.S. Department of Justice for its handling of residential mortgage-backed securities and related transactions. The Frankfurt, Germany-based lender said negotiations over the amount of the settlement are just beginning ... Software company says it warned Tesla ... Consumer prices rose 0.2% in August....
« back to news headlines
Study under way to combat HIV with antibodies
Edit Deccan Chronicle 17 Sep 2016
HIV-negative men and transgender individuals will prevent the deadly HIV infection from developing ... "It is the first study of this magnitude to see whether an antibody infusion can help prevent new HIV infections. If it proves effective, it could potentially pave a way for developing a vaccine for HIV infection," said Shobha ... partners are men, the highest-risk demographic for HIV infection, to test the efficacy of VRC01....
Vaccines: Not Just for Children (Texas Health Resources)
Edit Public Technologies 17 Sep 2016
Almost everyone is familiar with the seemingly never-ending litany of vaccines an infant gets and the rites of passage to get booster shots before entering kindergarten and high school. But is everyone in your family up to date on their vaccines?. 'Vaccines are critical for the prevention of certain infectious diseases,' said Dr ... 'Adults require certain vaccines as well as children.'....
NHS must fund HIV prevention drug prophylaxis (Liberal Democrats)
Edit Public Technologies 17 Sep 2016
The HIV preventative drug prophylaxis should be made available on the NHS for high-risk groups including gay men and BAME communities, the Liberal Democrats have urged. Pre-exposure prophylaxis (PrEP) is a once-a-day pill that reduces the risk of HIV infection by 86% ... has shown adopting PreP could prevent over 7400 new HIV infections by 2020....
Emory University awards Fulton County an “Emmy” for HIV screening program (Corizon Inc)
Edit Public Technologies 17 Sep 2016
The Corizon Health team in Fulton County, Georgia has received an 'Emmy Award' from Emory University recognizing their work in creating a nurse-led HIV screening program at the Fulton County Jail ... Atlanta is one of the most heavily HIV-affected areas in the nation ... 24/7 HIV testing rather than relying on outside health department staff....
Retro Posters Promote an Ancient Battle: Humans vs. Disease
Edit Slate 17 Sep 2016
Regular readers know I’m no fan of infectious diseases. Well, no one is, I suppose, but there are those who court them, thinking our body’s natural defenses are enough to prevent infection. Sometimes that’s true ... That’s why we need vaccines ... One group at the forefront of this is the Center for Infectious Disease Research, a non-profit organization that focuses on diseases like malaria, tuberculosis, HIV, and more ... Well said ... Period ... ....
Forced out by a funds squeeze
Edit The Hindu 17 Sep 2016
Kumari tested HIV positive in 2006 — after she contracted the virus during a premature delivery-linked blood transfusion — but it is now that they have started feeling its pinch ... Their job was to help HIV-positive pregnant women with their medication and monitor newborn babies. “We have seen discrimination in hospitals against HIV-positive women from such close quarters....
Ward 2 Office Hosts Free Rabies Vaccination Clinic (City of Tucson, AZ)
Edit Public Technologies 17 Sep 2016
City Councilmember Paul Cunningham and the Humane Society of Southern Arizona are teaming up for a vaccination clinic for dogs on Saturday, Sept ... At this free community event, dogs will receive a rabies vaccine....
Fear of having HIV among the most common phobias in Kolkata
Edit The Times of India 17 Sep 2016
From homophobia to scare of having HIV, from worry over not having mobile connectivity to fear of being touched - a large number of Kolkatans are experiencing all of these and even more ... A very common phobia that doctors have reported is the fear of having HIV ... They even go to the extent of getting HIV tests done ... Dissatisfied with repeated negative HIV tests, general physicians then refer them to psychiatrists....
Lifesaving UK investment in Global Fund announced (DfID - UK Department for International Development)
Edit Public Technologies 17 Sep 2016
As one of the world's most effective aid institutions, the Global Fund has saved millions of lives and delivered remarkable progress in the fight against HIV/AIDS, malaria and tuberculosis over the past 14 years ... Fund 40 million bednets to tackle malaria; Provide enough lifesaving anti-retroviral therapy for 1.3 million people with HIV; and Support the treatment of 800,000 people with tuberculosis....
Ben Parker cafeteria worker tests positive for hepatitis A
Edit Star Advertiser 17 Sep 2016
A letter from the principal sent home Friday advises parents to take children who have not yet been vaccinated to the doctor for possible vaccination. Most children in the state are protected from the disease through vaccination, which is recommended but not required for school entry ... of the hepatitis A vaccine, while 55 percent had the second dose....
Ben Parker Elementary cafeteria worker is latest hepatitis A food service case
Edit Star Advertiser 17 Sep 2016
Most children in the state are protected from the disease through vaccination, which is recommended but not required for school entry. A letter from the principal sent home today advises parents to take children who have not already been vaccinated to the doctor for possible vaccination or immune globulin....
Kenya donates largest contribution from Africa to combat HIV, TB and Malaria (Office of the President of the Government of Kenya)
Edit Public Technologies 17 Sep 2016
'The Global Fund has played a major role in supporting Kenya's success in combating HIV/Aids, Tuberculosis and Malaria over the years,' read CS Amina ... He said a global commitment could result in averting 28 million new HIV infections and 21 millions AIDS related deaths ... Kenya has 950,000 people living with HIV enrolled in life long anti-retroviral treatment, and who will receive ARVs for the next 70 years, if a cure is not found....
Comment on Ben Parker Elementary cafeteria worker is latest hepatitis A food service case by sailfish1
Edit Star Advertiser 17 Sep 2016
The worker only worked 3 days at the school. But, where else did this person work?. It’s probably too late now but shouldn’t our schools have required cafeteria workers to be vaccinated for Hepatitis A? Remember, not all students are vaccinated for Hepatitis A nor are all teachers and other school workers ... ....
- 1
- 2
- 3
- 4
- 5
- Next page »
